Clinical Trial Update: Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated acute peripheral vascular effects, safety and tolerability in patients with Raynaud's phenomenon secondary to systemic sclerosis. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Raynaud Phenomenon
• Systemic Sclerosis

Snippet

Sponsor: NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) | Conditions: Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Status: COMPLETED